Visceral fat accumulation and its relation to plasma hemostatic factors in healthy men

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 16, Issue 3, 1996, Pages 368-374

  Cigolini, M ^a   Targher, G ^a   Andreis, I A Bergamo ^a   Tonoli, M ^a   Agostino, G ^a   De Sandre, G ^a  

^a UNIVERSITY OF VERONA   (Italy)

Author keywords

fibrinogen; hemostatic factors; insulin; plasminogen activator inhibitor 1; visceral fat

Indexed keywords

BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; CHOLESTEROL; FIBRINOGEN; HEMOSTATIC AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPID; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD PRESSURE; BODY FAT; CONTROLLED STUDY; GLUCOSE TOLERANCE; HEMOSTASIS; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; VISCERA;

EID: 0029983028     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.16.3.368     Document Type: Article

References (36)

1. Kissebah AH, Krakower GR. Regional adiposity and morbidity. Physiol Rev. 1994;74:761-811.
2. Hamsten A. The hemostatic system and coronary heart disease. Thromb Res. 1993;70:1-38.
3. Meade TW, Ruddock V, Stirling Y, Chakrabarti RR, Miller GJ. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet. 1993;342:1076-1079.
4. Kannel WB, Wolf PA, Castelli WP, D'Agostino RB. Fibrinogen and risk of cardiovascular disease: the Framingham Study. JAMA. 1987;258:1183-1186.
5. Heinrich J, Balleisen L, Schulte H, Assman G, van de Loo JCW. Fibrinogen and factor VII in the prediction of coronary risk: results from the PROCAM study in healthy men. Arterioscler Thromb. 1994;14:54-59.
6. Thompson SG, Kienast J, Pyke SDM, Haverkate F, van de Loo JCW for the ECAT Angina Pectoris Study Group. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med. 1995;332:635-641.
7. Jansson JH, Nilsson TK, Johnson O. Von Willebrand factor in plasma: a novel risk for recurrent myocardial infarction and death. Br Heart J. 1991;66:351-355.
8. Folsom AR, Wu RR, Davis CE, Conlan MG, Sorlie PD, Szklo M. Population correlates of plasma fibrinogen and factor VII, putative cardiovascular risk factors. Atherosclerosis. 1991;91:191-205.
9. Juhan-Vague I, Alessi MC, Vague P. Increased plasma plasminogen activator inhibitor 1 levels: a possible link between insulin resistance and atherothrombosis. Diabetologia. 1991;34:457-462.
10. Dawson S, Henney A. The status of PAI-1 as a risk for arterial and thrombotic disease: a review. Atherosclerosis. 1992;95:105-117.
11. Cigolini M, Targher G, Seidell JC, Schiavon R, Manara F, Zenti MG, Mattioli C, De Sandre G. Relationships of plasminogen activator inhibitor-1 to anthropometry, scrum insulin, triglycerides and adipose-tissue fatty acids in healthy men. Atherosclerosis. 1994;106:139-146.
12. Cigolini M, Targher G, De Sandre G, Muggeo M, Seidell JC. Plasma fibrinogen in relation to scrum insulin, smoking habits and adipose-tissue fatty acids in healthy men. Eur J Clin Invest. 1994;24:126-130.
13. Conlan MG, Folsom AR, Finch A, Davis CE, Sorlie P, Marcucci G, Wu KK. Associations of factor VIII and von Willebrand factor with age, race, sex and risk factors for atherosclerosis: the Atherosclerosis Risk in Communities (ARIC) Study. Thromb Haemost. 1993;70:380-385.
14. Landin K, Stigendal L, Eriksson E, Krotkiewski M, Tengborn L, Smith U. Abdominal obesity is associated with an impaired fibrinolytic activity and elevated plasminogen activator inhibitor-1. Metabolism. 1990;39:1044-1048.
15. Vague P, Juhan-Vague I, Chabert V, Alessi MC, Atlan C. Fat distribution and plasminogen activator inhibitor activity in nondiabetic obese women. Metabolism. 1989;38:913-915.
16. Sundell B, Nilsson TK, Rånby M, Hallmans G, Hellsten G. Fibrinolytic variables are related to age, sex, blood pressure, and body build measurements: a cross-sectional study in Norsjö, Sweden. J Clin Epidemiol. 1989;42:719-723.
17. Eliasson M, Evrin PE, Lundblad D. Fibrinogen and fibrinolytic variables in relation to anthropometry, lipids and blood pressure: the Northern Sweden MONICA Study. J Clin Epidemiol. 1994;47:513-524.
18. Sundell IB, Dahlgren S, Rånby M, Lundin E, Stenling R, Nilsson TK. Reduction of elevated plasminogen activator inhibitor levels during modest weight loss. Fibrinolysis. 1989;3:51-53.
19. Folsom AR, Qamhieh HT, Wing RR, Jeffery RW, Stinson VL, Kuller LH, Wu KK. Impact of weight loss on plasminogen activator inhibitor-1 (PAI-1), factor VII, and other hemostatic factors in moderately overweight adults. Arterioscler Thromb. 1993;13:162-169.
20. van der Kooy K, Seidell JC. Techniques for the measurement of visceral fat: a practical guide. Int J Obes. 1993;17:187-196.
21. 40K, and tritium. Am J Physiol. 1986;250:E736-E745.
22. Cigolini M, Targher G, Tonoli M, Manara F, Muggeo M, De Sandre G. Hyperuricaemia: relationships to body fat distribution and other components of the insulin resistance syndrome in 38-year-old healthy men and women, Int J Obes. 1995;19:92-96.
23. World Health Organization. Diabetes mellitus: report of a WHO study group. Geneva, Switzerland: World Health Organization; 1985. Technical report series 727.
24. Rossi E, Mondonico P, Lombardi A, Preda L. Method for the determination of functional (clottable) fibrinogen by the new family of ACL coagulometers. Thromb Res. 1988;52:453-468.
25. Jansson JH, Olofsson BO, Nilsson TK. Predictive value of tissue plasminogen activator mass concentration on long-term mortality in patients with coronary artery disease: a 7-year follow-up. Circulation. 1993;88:2030-2034.
26. Ridker PM, Vaughan DE, Stampfer MJ, Manson JE, Hennekens CH. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet. 1993;341:1165-1168.
27. Gram J, Kluft C, Jespersen J. Depression of tissue plasminogen activator (t-PA) activity and rise of t-PA inhibition and acute phase reactants in blood of patients with acute myocardial infarction (AMI). Thromb Haemost. 1987;58:817-821.
28. Munkvad S, Gram J, Jespersen J. A depression of active tissue plasminogen activator in plasma characterizes patients with unstable angina who develop myocardial infarction. Eur Heart J. 1990;11:525-528.
29. Hamsten A, Eriksson P, Karpe F, Silveira A. Relationships of thrombosis and fibrinolysis to atherosclerosis. Curr Opin Lipidol. 1994;5:382-389.
30. Eliasson M, Asplund K, Evrin PE, Lindahl B, Lundblad D. Hyperinsulinaemia predicts low tissue plasminogen activator activity in a healthy population: the Northern Sweden MONICA Study. Metabolism. 1994;43:1579-1586.
31. Winocour PH, Neil AW, Farrer M, Kesteven P, Laker MF, Millar JP, Alberti KGMM. Serum insulin, haemostatic function and car- diovascular risk factors in normoglycaemic men and women. Nutr Metab Cardiovasc Dis. 1993;3:165-172.
32. Juhan-Vague I, Thompson SG, Jespersen J for the ECAT Angina Pectoris Study Group. Involvement of the hemostatic system in the insulin resistance syndrome: a study of 1500 patients with angina pectoris. Arterioscler Thromb. 1993;13:1865-1873.
33. Mykkänen L, Rönnemaa T, Marniemi J, Haffner SM, Bergmann R, Laakso M. Insulin sensitivity is not an independent determinant of plasma plasminogen activator inhibitor-1 activity. Arterioscler Thromb. 1994;14:1264-1271.
34. Asplund-Carlson A, Hamsten A, Wiman B, Carlson LA. Relationship between plasma fibrinogen activator inhibitor-1 activity and VLDL triglyceride concentration, insulin levels and insulin sensitivity: studies in randomly selected normo- and hypertriglyceridaemic men. Diabetologia. 1993;36:817-825.
35. Stiko-Rahm A, Wiman B, Hamsten A, Nilsson J. Secretion of plasminogen activator inhibitor-1 from cultured human umbilical vein endothelial cells is induced by very low-density lipoprotein. Arteriosclerosis. 1990;10:1067-1073.
36. Mussoni L, Mannucci L, Sirtori M, Camera M, Maderna P, Sironi L, Tremoli E. Hypertriglyceridemia and regulation of fibrinolytic activity. Arterioscler Thromb. 1992;12:19-25.